Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Microrna modulators and method for identifying and using the same

a technology of microrna and modulator, applied in the field of microrna modulator and method for identifying and using the same, can solve problems such as the effective delivery of such molecules, and achieve the effect of increasing or decreasing the expression of reporter proteins

Inactive Publication Date: 2010-08-05
WISTAR INSTITUTE +1
View PDF4 Cites 38 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention is a method for identifying a microRNA modulator by contacting a cell with a test agent and measuring the expression of a reporter protein. This method can also be used to identify diazobenzene, indenoisoquinoline, and cyclopentaphenanthrene miR-21 antagonists that can inhibit the activity of miR-21 microRNA and treat diseases associated with it.

Problems solved by technology

While specific miRNA inhibition has been achieved by antisense nucleic acid approaches, effective delivery of such molecules is an issue (Meister, et al.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Microrna modulators and method for identifying and using the same
  • Microrna modulators and method for identifying and using the same
  • Microrna modulators and method for identifying and using the same

Examples

Experimental program
Comparison scheme
Effect test

example 1

miRNA Inhibitor Screening Assay

[0054]MicroRNA miR-21 was selected as a target miRNA due to its involvement as an anti-apoptotic factor in cancer cells and its elevated levels in various cancers such as breast, ovarian, and lung cancer as well as glioblastoma (Chan, et al. (2005) Cancer Res. 65:6029). Lentiviral reporter constructs for miRNA activity were assembled by introducing the complementary sequences of mature miR-21 (5′-UAG CUU AUC AGA CUG AUG UUG A-3′; SEQ ID NO:13), miR-30A (5′-CUU UCA GUC GGA UGU UUG CAG C-3′; SEQ ID NO:14) as a specificity control, and a linker sequence (a previously present multiple-cloning site with no detectable recognition by natural miRNAs) downstream of a luciferase reporter gene as a negative control (FIG. 1).

[0055]Luc-miR-21, Luc-miR-30A, and Luc-linker (control) were, by viral infection, introduced into HeLa cells, which express high levels of miR-21, but only low levels of miR-30A (Cheng, et al. (2005) Nucl. Acids Res. 33:1290).

[0056]The specifi...

example 2

Identification of miR-21 Antagonists

[0058]To illustrate the method of the present invention, a primary screen of >1000 compounds was conducted. The library was composed of a collection of novel compounds and the Library of Pharmacologically Active Compounds (LOPAC library, Sigma-Aldrich, St Louis, Mo.). All compounds were stored at a 10 mM concentration in DMSO to keep the DMSO concentration in the actual screen at 0.1% thereby minimizing toxicity. HeLa cells stably expressing the miR-reporter were treated with DMSO ranging from 0.1-1%. Luciferase signals were determined 48 hours after the treatment.

[0059]HeLa cells (2500 cells) were plated in each well of 384-well plate 24 hour before the addition of compounds. Compounds at 10 μM final concentration were added to each well. Luciferase signal were determined 48 hours after compound treatment. Using this screening assay, compound 1 was identified as a miR-21 antagonist.

[0060]This diazobenzene led to an increase of the luciferase sign...

example 3

Synthesis of the Diazobenzene 2

[0067]

[0068]4-Phenylazobenzoic acid (30 mg, 0.133 mmol) was dissolved in DCM (1 mL), followed by the addition of 1-ethyl-3-(3′-dimethylaminopropyl)carbodiimide (42 mg, 0.22 mmol) and hydroxybenzotriazole (21 mg, 0.15 mmol). Propargylamine (15 mg, 0.27 mmol) was added and the reaction was stirred at room temperature for 12 hours. The reaction was quenched with water (5 mL) and extracted with DCM (3×5 mL). The organic layer was dried with sodium sulfate, concentrated and purified by silica gel chromatography (2:1 hexane / ethyl acetate) to yield an orange solid (29 mg, 0.11 mmol, 86%). 1H NMR (400 MHz, CDCl3) δ 7.98-7.92 (m, 6H), 7.57-7.49 (m, 3H), 6.46 (bs, 1H), 4.29 (dd, J1=2.4 Hz, J2=4.8 Hz, 2H), 2.13 (t, J=2.4, 1H); 13C NMR (75 MHz, CDCl3) δ 166.6, 154.6, 152.7, 135.6, 131.9, 129.4, 128.3, 123.4, 123.2, 79.5, 72.4, 30.2.

[0069]HRMS Calcd for C16H14N3O (MH+): 264.1131, Found: 264.1135.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
green fluorescentaaaaaaaaaa
red fluorescentaaaaaaaaaa
yellow fluorescentaaaaaaaaaa
Login to View More

Abstract

The present invention is a method for identifying agents which modulate microRNA activity. The invention involves contacting a cell harboring a microRNA and a microRNA binding sequence, which is operably linked to a nucleic acid molecule encoding a reporter protein, with a test agent and determining whether the test agent increases or decreases the expression of the reporter protein thereby identifying a microRNA modulator. Antagonists identified by this screening assay are provided, as are methods for using the same to inhibit microRNA activity and prevent or treat disease.

Description

INTRODUCTION[0001]This application is a Continuation-in-Part Application of PCT / US2009 / 034611, filed Feb. 20, 2009, which claims benefit of priority from U.S. Provisional Patent Application Ser. Nos. 61 / 029,971, filed Feb. 20, 2008, and 61 / 110,101, filed Oct. 31, 2008, the contents of which are incorporated herein by reference in their entireties.[0002]This invention was made with government support under grant number R21NS059478-01 awarded by the National Institutes of Health. The government has certain rights in the invention.BACKGROUND OF THE INVENTION[0003]MicroRNAs (miRNAs) are single-stranded noncoding RNAs of ˜22 nucleotides. They are a novel class of gene regulators that function by binding to the 3′ untranslated region of target messenger RNAs leading to either suppression of their translation or acceleration of their degradation (Bartel (2004) Cell 116:287; Carthew (2006) Curr. Opin. Genet. Dev. 16:203; He & Hannon (2004) Nat. Rev. Genet. 5:522; Cullen (2004) Mol. Cell. 16...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395C07C245/08A61K31/655C07D491/056A61K31/4355A61K31/566C07D413/14C07D405/04C07D487/04C07D487/00A61P35/00A61P9/00C07D487/18C12Q1/68
CPCC07D491/056C07D221/18A61P35/00A61P9/00
Inventor HUANG, QIHONGDEITERS, ALEXANDERGUMIREDDY, KIRANMAI
Owner WISTAR INSTITUTE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com